Information on the lab has been updated as has information on the status of the clinical trials.
Substantial progress has been made testing the drug screening platform. We are conducting a small scale pilot screen to verify we are ready for the final step, a full scale drug screen.
Work continues on defining the signaling pathways used by FGFR3.
Dr. Krejci will be returning to the Czech Republic in April for a faculty position and to spend more time with his children. We hope to continue to work with him on FGFR3 and wish him the best in his future research career.
A post-doctoral researcher will be recruited to continue the signaling pathway work to identify better therapeutic targets. New bioinformatics tools will be employed to assemble the available data into networks. This allows construction of a model for the pathways chondrocytes use even when there is missing data and lessens the need to dissect the pathways with extensive experimentation. The post-doc will also be evaluating lead compounds identified in the drug screen.
